Table 1 Demographic and clinical characteristics of study subjects taken at baseline of longitudinal study
From: Networks of blood proteins in the neuroimmunology of schizophrenia
|  | Unaffected comparison (UC) N = 35 | Clinical high-risk, nonconverters (CHR-NC) N = 40 | Clinical high-risk, Converters (CHR-C) N = 32 |
|---|---|---|---|
Age, average (SD) | 20 (4.5) | 19.5 (4.6) | 19.2 (3.7) |
Ancestry | |||
%Caucasian | 60%, | 65% | 55% |
%African | 31% | 17.5% | 21% |
%Asian | 9% | 17.5% | 24% |
Sex, % female | 34% | 37.5% | 30.3% |
SES, average (SD) | 4.8 (1.8) | 4.5 (2.3) | 4.5 (1.8) |
Time blood draw, average (SD) | 12.:12 pm (1.85 h) | 12:39 pm (2.0 h) | 11:59 am (1.79 h) |
Prescription medication | |||
Antipsychotica | 0% | 25% | 13% |
Antidepressantb | 1% | 30% | 25% |
Stimulant | 0% | 8% | 6% |
Mood stabilizer | 0% | 5% | 3% |
Benzodiazepinec | 0% | 5% | 13% |
NSAID | 0% | 0% | 0% |
Antibiotic | 0% | 0% | 0% |
Substance Use | |||
Tobacco used | 9% | 30% | 44% |
Alcohol use | 46% | 48% | 38% |
Marijuana usee | 9% | 25% | 31% |
Current co-morbid DSM IV Diagnosis | |||
Depressionf | 0% | 45% | 50% |
Anxiety Disordersg,* | 3% | 60% | 56% |
